Floatz logo

eik1005

MSI-H/dMMR Gastroesophageal-junction Cancer

Eikon TherapeuticsPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

112 Active assets in the MSI-H/dMMR Gastroesophageal-junction Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

eik1005 is also rated in:

MSI-H or dMMR Advanced Solid TumorsDormant
CCC
Indicative ·
48 / 100
View asset →
gastric cancerDormant
CCC
Indicative ·
48 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →